Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dihydropyrimidine Dehydrogenase (DPD) Phenotype-guided Dose Individualization of Fluoropyrimidine-based Chemotherapy in DPD Deficient Patients With Gastrointestinal Cancers

NCT06475352 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT06475352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06475352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dihydropyrimidine Dehydrogenase (DPD) Phenotype-guided Dose Individualization of Fluoropyrimidine-based Chemotherapy in DPD Deficient Patients With Gastrointestinal Cancers
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Recruiting
Start date
January 20, 2025
Completion date
January 31, 2030
Enrollment
400 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, digestive cancer